Tumor Board: Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss current and emerging therapeutic options for first- and second-line treatment of EGFR-mutated NSCLC
• Formulate appropriate strategies for the management of adverse effects related to EGFR targeted therapies in NSCLC
• ·Develop individualized treatment plans for patients with EGFR-mutant NSCLC by implementing new data and guideline-recommended strategies

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca.

Chair:

Tina Cascone, MD, PhD

Associate Professor
Physician-Scientist Director of Translational Research
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Consultant: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Merck, oNKo-Innate, Pfizer, RAPT Therapeutics, Summit Therapeutics; Grant/Research Support: AstraZeneca, Bristol Myers Squibb; Speaker’s Bureau: The ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, IDEOlogy Health, Medical Educator Consortium, Medscape

Faculty:

Christina Baik, MD, MPH

Thoracic, Head and Neck Medical Oncology
Fred Hutchinson Cancer Center
University of Washington School of Medicine
Seattle, WA

Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Boehringer, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Janssen, Lilly, Natera, Nuvalent, Pfizer, Regeneron; Grant/Research Funding: Abbvie, AstraZeneca, Black Diamond, Blueprint Medicines, Boehringer, Bristol Myers Squibb, Daiichi Sankyo, Ellipses, Janssen, Lilly, Nuvalent, Pfizer, Systimmune, Turning Point Therapeutics

David Planchard, MD, PhD

Head of Thoracic Group
Department of Medical Oncology
Institut Gustave Roussy
Villejuif, France

Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AbbVie, ArriVent, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, GSK, Janssen, Merck, Mirati, Novartis, Pfizer, Roche, Pierre Fabre, Seagen, Takeda; Clinical trials research as principal or co-investigator (institutional financial interests): AbbVie, ArriVent, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Janssen, Medimmune, Merck, Mirati, Novartis, Novocure, Pfizer, Pierre Fabre, Roche, Sanofi-Aventis, Seagen, Taiho Pharma, Takeda; Travel/Accommodations/Expenses: AstraZeneca, Novartis, Pfizer, Roche

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on adjuvant treatment of early stage EGFR-mutant non-small cell lung cancer and targeting resistance mechanisms in metastatic disease, go to https://www.gotoper.com/wclc25egfr-enduring.

Release Date

October 24, 2025

Expiration Date

October 24, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.